menu search

ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results

ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
Key Highlights: Advanced clinical development initiatives for Cholesterol Efflux Mediator™ VAR 200, with planned initiation of a Phase 2a clinical trial in diabetic kidney disease (DKD) in the first quarter of 2024 Granted a European patent covering Phase 2a-ready Cholesterol Efflux MediatorTM VAR 200 (2-hydroxypropyl-beta-cyclodextrin) for use in diabetic nephropathy/diabetic kidney disease Published new white […] The post ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial... Read More
Posted: Aug 21 2023, 20:15
Author Name: forextv
Views: 101976

Search within

Pages Search Results: